Cucurbitacin E
Based on 6 publication(s) in Google Scholar
Cucurbitacin E is a CDK1 inhibitor that significantly inhibits the activity of the cyclin B1/CDC2 complex. Cucurbitacin E also induces PANoptosis in adrenocortical carcinoma cells in a ZBP1-dependent manner. Cucurbitacin E exhibits synergistic effects with Mitotane (HY-13690); when used in combination, they effectively eliminate tumors.
For research use only. We do not sell to patients.
- Purity: 99.92%
- CAS No.: 18444-66-1
- Formula: C32H44O8
- Molecular Weight:556.69
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Cucurbitacin E
More-
WB
Biological Activity
|
cyclin B1/CDC2 |
Autophagy |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Cancer cell lines | IC50 |
<0.4 μM
Compound: Cucurbitacin E
|
Growth inhibition of human breast cancer cells
Growth inhibition of human breast cancer cells
|
[PMID: 15332833] |
| Cancer cell lines | IC50 |
<0.4 μM
Compound: Cucurbitacin E
|
Growth inhibition of human CNS cancer cells
Growth inhibition of human CNS cancer cells
|
[PMID: 15332833] |
| Cancer cell lines | IC50 |
<0.4 μM
Compound: Cucurbitacin E
|
Growth inhibition of human colon cancer cells
Growth inhibition of human colon cancer cells
|
[PMID: 15332833] |
| Cancer cell lines | IC50 |
<0.4 μM
Compound: Cucurbitacin E
|
Growth inhibition of human lung cancer cells
Growth inhibition of human lung cancer cells
|
[PMID: 15332833] |
| Cancer cell lines | IC50 |
7 nM
Compound: Cucurbitacin E
|
Growth inhibition of human prostate cancer cells
Growth inhibition of human prostate cancer cells
|
[PMID: 15332833] |
| Cancer cell lines | IC50 |
7 nmol
Compound: Cucurbitacin E
|
Growth inhibition of human prostate cancer cells
Growth inhibition of human prostate cancer cells
|
[PMID: 15332833] |
| HeLa | IC50 |
0.1 μM
Compound: 12
|
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
|
[PMID: 21459003] |
| HepG2 | EC50 |
3.2 μM
Compound: 12
|
Hepatoprotective activity in human HepG2 cells assessed as inhibition of CCl4-induced toxicity after 24 hrs by MTT assay
Hepatoprotective activity in human HepG2 cells assessed as inhibition of CCl4-induced toxicity after 24 hrs by MTT assay
|
[PMID: 21459003] |
| HepG2 | IC50 |
15.25 μM
Compound: 12
|
Cytotoxicity against human HepG2 cells after 24 hrs assessed as inhibition of cell viability by MTT assay
Cytotoxicity against human HepG2 cells after 24 hrs assessed as inhibition of cell viability by MTT assay
|
[PMID: 21459003] |
| HL-60 | IC50 |
18 nM
Compound: 1
|
Cytotoxicity against human HL60 cells after 72 hrs by WST-8 assay
Cytotoxicity against human HL60 cells after 72 hrs by WST-8 assay
|
[PMID: 20347305] |
| HSC-T6 | EC50 |
0.04 μM
Compound: 12
|
Antiproliferative activity against serum-stimulated rat HSC-T6 cells after 24 hrs by MTT assay
Antiproliferative activity against serum-stimulated rat HSC-T6 cells after 24 hrs by MTT assay
|
[PMID: 21459003] |
| HSC-T6 | IC50 |
2.03 μM
Compound: 12
|
Cytotoxicity against rat HSC-T6 cell after 24 hrs by MTT assay
Cytotoxicity against rat HSC-T6 cell after 24 hrs by MTT assay
|
[PMID: 21459003] |
| HT-1080 | IC50 |
40 nM
Compound: 1
|
Cytotoxicity against human HT1080 cells after 72 hrs by WST-8 assay
Cytotoxicity against human HT1080 cells after 72 hrs by WST-8 assay
|
[PMID: 20347305] |
| JY | IC50 |
0.18 μM
Compound: 1
|
Inhibition of LFA1 expressed in human JY cells interaction with ICAM1-IG expressed in human HeLa cell monolayer after 45 mins by cell adhesion assay
Inhibition of LFA1 expressed in human JY cells interaction with ICAM1-IG expressed in human HeLa cell monolayer after 45 mins by cell adhesion assay
|
[PMID: 7852999] |
| MCF7 | IC50 |
0.055 μM
Compound: 8
|
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTS/PMS assay
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTS/PMS assay
|
[PMID: 25756299] |
| U-937 | IC50 |
16 nM
Compound: 1
|
Cytotoxicity against human U937 cells after 72 hrs by WST-8 assay
Cytotoxicity against human U937 cells after 72 hrs by WST-8 assay
|
[PMID: 20347305] |
Cucurbitacin E (2.5-7.5 μM; 6-24 h) induces morphological changes in primary colon cancer cells and inhibits tumor growth by arresting the cell cycle at the G2/M phase through the induction of GADD45γ gene expression and the blockade of the Cyclin B1/CDC2 complex in primary CRC cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 18444-66-1
-
Appearance Solid
-
Molecular Weight 556.69
-
Formula C32H44O8
-
Color White to off-white
-
SMILES
O[C@H](C1)[C@@]([C@@](C)(O)C(/C=C/C(OC(C)=O)(C)C)=O)([H])[C@](C2)(C)[C@]1(C)[C@]3([H])CC=C4C(C)(C)C(C(O)=C[C@@]4([H])[C@]3(C)C2=O)=O
-
Synonyms
α-Elaterin; α-Elaterine
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Drp1-dependent remodeling of mitochondrial morphology triggered by EBV-LMP1 increases cisplatin resistance. [Abstract]2020 May 20;5(1):56. PMID: 32433544
Cucurbitacin E purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2020 May 20;5(1):56. [Abstract]
Western Blot is performed to determine the protein levels of cyclin B1, Cdk1, and p-Drp1 Ser616. LMP1-positive cells are treated with or without cucurbitacin E (10 μM) for 24 h.
-
J Transl Med
Cucurbitacin E reduces IL-1β-induced inflammation and cartilage degeneration by inhibiting the PI3K/Akt pathway in osteoarthritic chondrocytes. [Abstract]2023 Dec 4;21(1):880. PMID: 38049841 -
J Transl Med
CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2/M phase transition, and PANoptosis. [Abstract]2022 Oct 2;20(1):444. PMID: 36184616 -
Chin Med
Cucurbitacin E inhibits cellular proliferation and induces apoptosis in melanoma by suppressing HSDL2 expression. [Abstract]2022 Feb 22;17(1):28. PMID: 35193614 -
Curr Issues Mol Biol
Cucurbitacin E Exerts Anti-Proliferative Activity via Promoting p62-Dependent Apoptosis in Human Non-Small-Cell Lung Cancer A549 Cells. [Abstract]2023 Oct 7;45(10):8138-8151. PMID: 37886957 -
Solvent & Solubility
DMSO : 50 mg/mL (89.82 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (4.49 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
The colorectal cancer (CRC) cells are seeded into 96-well culture plates at 5000 cells/well. The cells are treated with 0, 2.5, 5, and 7.5 μM Cucurbitacin E for 1-3 days. MTT dye (1 mg/mL) is added to each well for at least 4 h of treatment. The reaction is stopped by the addition of DMSO, and optical density is measured at 540 nm on a multi-well plate reader. Background absorbance of the medium in the absence of cells is subtracted. All samples are assayed in triplicate, and the mean for each experiment is calculated. Results are expressed as a percentage of control, which is considered as 100%. Each assay is carried out in triplicate, and the results are expressed as the mean[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[2]
C57BL/6 male mice are used. The mice are designated as metabolic syndrome mice (HFD-MetS-mice). Briefly, the mice are randomly assigned into two groups according to their diet for 8 weeks (n = 10-12): high fat diet group (HFD) (60% fat, 20% carbohydrate, 20% protein) or the matched low fat, standard diet group (SD) (10% fat, 70% carbohydrate, 20% protein). After eight weeks on high fat diet, the mice with significant obese phenotype and fasting blood glucose levels ≥126 mg/dL are considered MetS mice. The MetS mice are continued on the HFD throughout the study. The MetS mice are then randomly divided into three additional groups, according to the treatment administered by oral gavage for 10 weeks (n=10-12): a low dose 0.25 mg/kg/day of Cucurbitacin E designated as HFD+Cucurbitacin E (L) or high dose 0.5 mg/kg/day of Cucurbitacin E, designated as HFD+Cucurbitacin E (H) or 50 mg/kg/day Orlistat (HFD+Orlistat). Animals on SD are administered 0.5% CMC by oral gavage[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Hsu YC, et al. Therapeutic ROS targeting of GADD45γ in the induction of G2/M arrest in primary human colorectal cancer cell lines by cucurbitacin E. Cell Death Dis. 2014 Apr 24;5:e1198. [Content Brief]
[2]. Murtaza M, et al. Cucurbitacin E reduces obesity and related metabolic dysfunction in mice by targeting JAK-STAT5 signaling pathway. PLoS One. 2017 Jun 9;12(6):e0178910. [Content Brief]
[3]. Wang L, et al. Mechanisms of PANoptosis and relevant small-molecule compounds for fighting diseases. Cell Death Dis. 2023 Dec 21;14(12):851. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7963 mL | 8.9817 mL | 17.9633 mL | 44.9083 mL |
| 5 mM | 0.3593 mL | 1.7963 mL | 3.5927 mL | 8.9817 mL | |
| 10 mM | 0.1796 mL | 0.8982 mL | 1.7963 mL | 4.4908 mL | |
| 15 mM | 0.1198 mL | 0.5988 mL | 1.1976 mL | 2.9939 mL | |
| 20 mM | 0.0898 mL | 0.4491 mL | 0.8982 mL | 2.2454 mL | |
| 25 mM | 0.0719 mL | 0.3593 mL | 0.7185 mL | 1.7963 mL | |
| 30 mM | 0.0599 mL | 0.2994 mL | 0.5988 mL | 1.4969 mL | |
| 40 mM | 0.0449 mL | 0.2245 mL | 0.4491 mL | 1.1227 mL | |
| 50 mM | 0.0359 mL | 0.1796 mL | 0.3593 mL | 0.8982 mL | |
| 60 mM | 0.0299 mL | 0.1497 mL | 0.2994 mL | 0.7485 mL | |
| 80 mM | 0.0225 mL | 0.1123 mL | 0.2245 mL | 0.5614 mL |